Remote ALS Research Study Expansion

The MDA MOVR program has paired with Mitsubishi Tanabe Pharma America, Inc. (MTPA) to collaborate on a remote observational research study focusing on amyotrophic lateral sclerosis (ALS).

Study Details & Benefits:

• Purpose: This study aims to see if digital tools, like tablets and smartwatches, can reliably track ALS symptoms at home over 1 year.
• Compensation: Participants will receive up to $100 in gift cards.
• Eligibility: You must be 18-90 years old, have a diagnosis of definite, probable, or possible ALS, be able to write (even if it’s not always legible), and use utensils to cut food (with or without help).

This is not a treatment study, therefore if you are participating in an ALS drug trial you would not be excluded from enrolling in this study.

• Participation: You’ll complete monthly assessments at home using an Apple iPad and wear a Fitbit watch during the day. These devices will be provided to you at no cost.
• Duration: The study lasts for 12 months.
• Enrollment: Up to 75 participants will be enrolled.

Why This Study Matters?

Using digital tools from home could change how ALS clinical trials are done in the future, making them more accessible and less burdensome for patients.

Click here for more information and registration.

You do not need to be a participant in the MOVR study to enroll in this study